Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Century Therapeutics Inc (NASDAQ: IPSC) closed at $0.56 down -7.01% from its previous closing price of $0.60. In other words, the price has decreased by -$7.01 from its previous closing price. On the day, 0.59 million shares were traded. IPSC stock price reached its highest trading level at $0.5996 during the session, while it also had its lowest trading level at $0.55.
Ratios:
For a deeper understanding of Century Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.39 and its Current Ratio is at 10.39. In the meantime, Its Debt-to-Equity ratio is 0.28 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on August 08, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On August 28, 2023, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $28 to $5.
On December 27, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $19.Chardan Capital Markets initiated its Buy rating on December 27, 2022, with a $19 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 10 ’25 when Pfeiffenberger Brent sold 2,235 shares for $0.61 per share. The transaction valued at 1,375 led to the insider holds 1,190,310 shares of the business.
Russotti Gregory sold 2,360 shares of IPSC for $1,451 on Mar 10 ’25. The insider now owns 272,573 shares after completing the transaction at $0.61 per share. On Mar 10 ’25, another insider, Farid Adrienne, who serves as the Chief Operations Officer of the company, sold 2,359 shares for $0.61 each. As a result, the insider received 1,451 and left with 131,717 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IPSC now has a Market Capitalization of 47488696 and an Enterprise Value of -96027280. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.65 while its Price-to-Book (P/B) ratio in mrq is 0.24. Its current Enterprise Value per Revenue stands at -35.778 whereas that against EBITDA is 0.814.
Stock Price History:
The Beta on a monthly basis for IPSC is 1.72, which has changed by -0.8882 over the last 52 weeks, in comparison to a change of 0.07903516 over the same period for the S&P500. Over the past 52 weeks, IPSC has reached a high of $5.24, while it has fallen to a 52-week low of $0.57. The 50-Day Moving Average of the stock is -30.81%, while the 200-Day Moving Average is calculated to be -65.33%.
Shares Statistics:
For the past three months, IPSC has traded an average of 516.43K shares per day and 409980 over the past ten days. A total of 84.76M shares are outstanding, with a floating share count of 36.09M. Insiders hold about 57.55% of the company’s shares, while institutions hold 31.62% stake in the company. Shares short for IPSC as of 1740700800 were 3405739 with a Short Ratio of 6.59, compared to 1738281600 on 3068788. Therefore, it implies a Short% of Shares Outstanding of 3405739 and a Short% of Float of 4.9000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Century Therapeutics Inc (IPSC) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.42 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.59 and -$1.66 for the fiscal current year, implying an average EPS of -$1.62. EPS for the following year is -$1.88, with 4.0 analysts recommending between -$1.79 and -$1.98.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $975k this quarter.It ranges from a high estimate of $2M to a low estimate of $100k. As of the current estimate, Century Therapeutics Inc’s year-ago sales were $268k
A total of 5 analysts have provided revenue estimates for IPSC’s current fiscal year. The highest revenue estimate was $4.4M, while the lowest revenue estimate was $2.52M, resulting in an average revenue estimate of $3.35M. In the same quarter a year ago, actual revenue was $2.23M
